Oragenics Inc is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious diseases and on developing effective treatments for oral mucositis. Oragenics involves developing its antibiotic product candidate, OG716 as well as other ho... Oragenics Inc is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious diseases and on developing effective treatments for oral mucositis. Oragenics involves developing its antibiotic product candidate, OG716 as well as other homolog antibiotic product candidates, researching LBPs, and having other product candidates, including SMaRT Replacement Therapy positioned for out-licensing or partnering. It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus. 더 보기
SARASOTA, Fla., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
SARASOTA, Fla., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
• Falls and car accidents lead incidence of concussions in emergency departments • Spray-dried drug formulation allows for easy delivery to patients • No pharmaceutical treatment is available...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.83 | -61.0294117647 | 1.36 | 1.41 | 0.47 | 738397 | 0.83830577 | CS |
4 | -1.04 | -66.2420382166 | 1.57 | 2.52 | 0.47 | 750969 | 1.29279079 | CS |
12 | -0.92 | -63.4482758621 | 1.45 | 3.43 | 0.47 | 395928 | 1.38820194 | CS |
26 | -2.61 | -83.1210191083 | 3.14 | 7.74 | 0.47 | 222544 | 1.50670772 | CS |
52 | -40.822 | -98.7183207584 | 41.352 | 46.194 | 0.47 | 595365 | 24.80101055 | CS |
156 | -32.47 | -98.3939393939 | 33 | 127.2 | 0.47 | 3063463 | 49.51238235 | CS |
260 | 0 | 0 | 0 | 0.55 | 0 | 0 | 0 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관